Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, gave a talk on “Patent Protection & Strategy: What a Startup Company Should Know” at the Pi Centre of The Chinese University of Hong Kong.
我們過去活動
Recommended Insights
US vs CN: Foreign Filing License Requirements
2022年11月9日In China, foreign filing requirements are generally very similar to the US — a foreign filing license is required if a foreign application is to be filed first for an invention made in the country. The Chinese equivalent to the US foreign filing license is called a confidentiality examination for foreign filing. According to Chinese […]
閱讀更多 >
China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision
2022年9月21日China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
閱讀更多 >
Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement
2024年1月9日Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]
閱讀更多 >
Compositions Limited by Use: A Cautionary Tale
2022年10月26日Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
閱讀更多 >